» Articles » PMID: 12590950

Markers of Platelet Activation and Platelet-leukocyte Interaction in Patients with Myeloproliferative Syndromes

Overview
Journal Thromb Res
Date 2003 Feb 20
PMID 12590950
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Changes in platelet count and function contribute to thrombo-hemorrhagic episodes in chronic myeloproliferative syndromes (MPS). We used flow cytometry to study platelet-leukocyte conjugates and markers of platelet activation in patients with MPS.

Methods: Whole blood from patients with chronic myelogenous leukemia (CML), polycythemia vera (PV), chronic myelofibrosis (MF), and essential thrombocythemia (ET) and from healthy volunteers was prepared for flow cytometry. Platelet microparticles and platelet microaggregates were identified with anti-CD42b and forward scatter, activated platelets with anti-CD62p. Anti-CD42b, anti-CD14, and anti-CD45 were used to study platelet-leukocyte conjugates.

Results: The percentage of CD62p-positive platelets was elevated in all myeloproliferate syndrome subtypes. The median percentage of platelet microparticles was 5.2% in controls and significantly higher in PV (12.0%), MF (11.0%), and ET (11.0%, all p<0.05). There was an increased percentage of platelet-neutrophil conjugates in patients with PV (8.3%) and ET (10.4%) compared to normal controls (6.8%, all p<0.05). Platelet-monocyte conjugates were 8.0% in controls and elevated in PV (15.4%) and ET (15.0%, all p<0.05). Patients with a history of venous or arterial thrombotic events had slightly less platelet-leukocyte conjugates and slightly more microparticles than patients without thrombosis; however, this difference was not statistically significant.

Conclusions: These findings suggest that platelet-leukocyte conjugate formation occurs in myeloproliferative syndromes and indicates platelet activation. Also, platelet microparticles are elevated and might provide a catalytic surface for thrombin generation. This could explain the clinical observation that patients with myeloproliferative syndromes have an increased risk to experience arterial or venous thrombotic events.

Citing Articles

Extracellular Traps Increase Burden of Bleeding by Damaging Endothelial Cell in Acute Promyelocytic Leukaemia.

Wang Y, Wang C, Zuo N, Yang H, Fang S, Shi J Front Immunol. 2022; 13:841445.

PMID: 35479063 PMC: 9035902. DOI: 10.3389/fimmu.2022.841445.


Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review.

Gaman M, Cozma M, Dobrica E, Cretoiu S, Gaman A, Diaconu C Life (Basel). 2021; 11(7).

PMID: 34357048 PMC: 8304270. DOI: 10.3390/life11070677.


Soluble P-selectin and correlation with Prothrombin Fragment 1 + 2 in myeloid malignancies in Cipto Mangunkusumo general hospital.

Sukrisman L Thromb J. 2021; 19(1):51.

PMID: 34330290 PMC: 8325311. DOI: 10.1186/s12959-021-00307-5.


Platelet Microparticle Controversial Role in Cancer.

Nazari M, Javandoost E, Talebi M, Movassaghpour A, Soleimani M Adv Pharm Bull. 2021; 11(1):39-55.

PMID: 33747851 PMC: 7961228. DOI: 10.34172/apb.2021.005.


A Broad Overview of Signaling in -Negative Classic Myeloproliferative Neoplasms.

Guijarro-Hernandez A, Vizmanos J Cancers (Basel). 2021; 13(5).

PMID: 33652860 PMC: 7956519. DOI: 10.3390/cancers13050984.